However, Regorafenib led to an increase in the proportion of highly proliferating tumors with a Ki-67 index higher 55% both during early and later tumor development, suggesting a potential survival disadvantage following Regorafenib treatment at least in this subset of tumors. This evidence concerns the gene MKI67 and neoplasm.